HDAC1 and liver cancer: High expression of HDAC1 and HDAC2 in hepatocellular carcinoma cells can reduce the acetylation level of H3K27 in the enhancer region of FBP1, and the use of HDAC1 and HDAC2 inhibitors can restore the acetylation of H3K27 in the enhancer region of FBP1, thereby inhibiting glucose metabolism and the growth of liver cancer cells (46).